Table 2

Frequency of the autoantibodies assessed before therapy and at different times after initiation of infliximab treatment

Antibody

Positivity (n [%])

P valuea


Before therapy

From start of infliximab treatment


30 weeks

54 weeks

78 weeks


ANA

15/30 (50)

21/30 (70)

23/30 (76.7)

24/30 (80)

0.0292

Anti-dsDNA (ELISA)

2/30 (6.7)

3/30 (10)

5/30 (16.7)

0/30 (0)

0.4915

Anti-dsDNA (IIF)

1/30 (3.3)

1/30 (3.3)

2/3 (6.7)

1/30 (3.3)

-

Anti-ENAb

3/30 (10)

4/30 (13.3)

4/30 (13.3)

4/30 (13.3)

0.999

aCL IgG

0/30 (0)

1/30 (3.3)

2/30 (6.7)

2/30 (6.7)

0.4915

aCL IgM

0/30 (0)

1/30 (3.3)

2/30 (6.7)

3/30 (10)

0.2373

ANCA

0/30 (0)

0/30 (0)

0/30 (0)

0/30 (0)

-

RF

26/30 (86.7)

27/30 (90)

25/30 (83.3)

24/30 (80)

0.7306

Anti-CCP

25/30 (83.3)

22/30 (73.3)

22/30 (73.3)

25/30 (83.3)

-

EMA (IIF)

0/30 (0)

0/30 (0)

0/30 (0)

0/30 (0)

-


aComparison between 0 and 78 weeks. bOnly anti-SSA(Ro) reactivity was found. ACL, anticardiolipin; ANA, antinuclear antibody; ANCA, antineutrophil cytoplasmic antibody; CCP, cyclic citrullinated peptide; DAS 28, Disease Activity Score; ds, double-stranded; ELISA, enzyme-linked immunosorbent assay; EMA, antiendomysial antibody; ENA, extractable nuclear antigen; IIF, indirect immunofluorescence; RF, rheumatoid factor.

Bobbio-Pallavicini et al. Arthritis Res Ther 2004 6:R264-R272   doi:10.1186/ar1173

Open Data